Aktiesnakken — September 2013
-
det var kun en for en kort bemærkning. køb i 14 solgt i 21
-
det handler om at der er flere puf i cigaren for selve casen er noget kreperligt lort
-
og samme analyse gælder for stort set alle de aktier af anden "etnisk" oprindelse
-
Længere interview med David Solomon: http://medwatch.dk/secure/Medicinal___Biotek/article5944478.ece
-
pæn omsætning i genmab
-
Ja C20 er meget sikker pt.

-
hvis vi taler genmab så er den jo lige steget fra 170 så jeg er glad
-
Norden i 234! det er gået stærkt!
-
man skal hele tiden have et stramt øje på deres finanser
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind